Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC-TB: Adjunctive N-acetylcysteine in Pulmonary Tuberculosis
NCT03702738Phase 2Completed
- Sponsor
- Aurum Institute
- Start
- Mar 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acetylcysteine in pulmonary tuberculosis (TB) (2 arms), sponsored by Aurum Institute. Primary endpoint: Median time to stable sputum culture conversion using liquid medium at 6 months. Started Mar 2019; status: completed.
02
Drugs
acetylcysteine
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT03702738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702738.